CLINICAL TRIAL HUMAN (30 Day)
The Study results showed that kollaGen II-xs™ when taken at a dosage of 375mg – 500mg twice per day appears to benefit joint inflammation, secondary mobility and other tertiary effects. The study shows that kollaGen II-xs™ taken at a dosage of 1500mg – 25mg daily significantly reduced pain and inflammatory response.
- General Pain (87.9% reduction; P=0.007)
- Range of Motion Associated Pain (76.1% reduction; P=0.021)
- Flexibility (62.4% increase; P=0.005)
The study also showed a normalizing of Saliva pH levels which is often indicative of a a reduction in inflammation. Collagen Type II is the major component of joint cartilage.